Management of Resistant Hypertension in Non-Adherent Patients

Introduction to Resistant Hypertension Management

The European Society of Cardiology recommends that for non-adherent patients with resistant hypertension, spironolactone 25-50 mg daily added to a simplified once-daily single-pill combination regimen is the most effective strategy to improve both blood pressure control and medication adherence 1

Simplifying the regimen to once-daily dosing using single-pill combinations improves adherence compared to multiple separate medications, as suggested by the American Diabetes Association 2, 3
Identifying and addressing specific barriers including medication cost, side effects, and dosing complexity that contribute to non-adherence is crucial, according to the American Diabetes Association 2, 4

The foundation regimen should include a long-acting thiazide-like diuretic, a dihydropyridine calcium channel blocker, and an ACE inhibitor or ARB at maximum tolerated dose, as recommended by the European Society of Cardiology 1, 2
Adding spironolactone 25 mg daily, titrating to 50 mg if tolerated, is the single most effective fourth-line agent for resistant hypertension, reducing office systolic BP by -13.30 mmHg and 24-hour systolic BP by -8.46 mmHg, as established by the European Society of Cardiology 1, 2, 4

Critical monitoring for serum potassium and creatinine is necessary, especially when combining spironolactone with ACE inhibitors/ARBs, as advised by the American Diabetes Association 2, 4, 7
If spironolactone is not tolerated or contraindicated, alternative fourth-line agents include eplerenone, amiloride, bisoprolol, or doxazosin, as suggested by the European Society of Cardiology 1, 4, 6

The American Heart Association recommends lifestyle interventions as the most effective non-pharmacological treatment, including sodium restriction to <2400 mg/day, weight loss if overweight/obese, regular exercise program, and limiting alcohol to ≤2 drinks/day for men, ≤1 drink/day for women 1, 5, 7

The American Diabetes Association advises against adding multiple agents simultaneously in non-adherent patients, as this worsens adherence, and against using ACE inhibitor + ARB combinations due to increased adverse events without additional benefit 2, 4
Monitoring for hyperkalemia vigilantly when combining spironolactone with ACE inhibitors/ARBs is crucial, especially in elderly patients or those with renal impairment, as recommended by the American Diabetes Association 2, 4, 7